Nasdaq:JAZZ
Jazz Pharmaceuticals plc
A US-based specialty pharma firm leveraging its expertise in complex disease areas to commercialize high-value oncology and orphan drug portfolios.
Key Metrics
Investment Thesis
Bull Case
Investors may consider this stock if they believe the company can successfully pivot its cost structure to restore profitability after the recent earnings miss. The diverse portfolio of complex disease therapies offers multiple avenues for growth through new indications and international expansion in markets where Jazz has a strong presence. Long-term value could be unlocked by successful commercialization of upcoming pipeline assets that address significant unmet medical needs.
Bear Case
The recent shift to a net loss and negative operating profit indicates fundamental operational challenges that warrant caution before entering a position. High levels of long-term debt relative to equity, combined with a large accumulated deficit, limit financial flexibility during periods of market volatility. Investors should avoid the stock until the company demonstrates a clear path to sustainable profitability and stabilizes its cash flow from operations.
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a specialty pharmaceutical company focused on developing and commercializing high-value medicines for complex diseases. The company primarily serves markets in the United States, Europe, and Japan with a portfolio centered on oncology, orphan diseases, and rare conditions. Key products include targeted therapies like Jevtana and Zynquista, supported by a strong pipeline of novel biologics.
Analysis
Management Discussion
Despite a strong historical revenue growth trajectory from $3.66B in 2022 to $4.27B in 2025, the company's profitability has deteriorated sharply with a net loss of $356.1M in 2025 compared to a profit of $560.1M in 2024. This reversal is reflected in negative operating profits and significant cash outflows from investing activities, suggesting potential headwinds in R&D spend or commercial performance.
Industry Overview
The specialty pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition for differentiated therapies in complex disease areas. Companies in this space must navigate evolving global healthcare policies while managing long development cycles and significant commercialization risks to achieve market success. Success often depends on the ability to secure favorable reimbursement terms and build specialized distribution networks.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $3.66B | $3.83B | $4.07B | $4.27B |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $3.66B | $3.83B | $4.07B | $4.27B |
| Operating Expenses | $3.72B | $3.26B | $3.35B | $4.70B |
| Operating Income | $-65.5M | $578.6M | $716.6M | $-430.2M |
| G&A | $1.42B | $1.34B | $1.39B | $1.81B |
| Stock-Based Comp | $222.0M | $226.8M | $248.0M | $291.1M |
| D&A | $30.3M | $30.4M | $32.8M | $41.6M |
| Depreciation | $30.3M | $30.4M | $32.8M | $41.6M |
| Amortization | $599.2M | $608.3M | $627.3M | $654.7M |
| Other OpEx | $2.31B | $1.91B | $1.97B | $2.89B |
| Non-Operating Income | $-307.3M | $-280.7M | $-246.3M | $-197.6M |
| Interest Income | $11.5M | $65.1M | $106.3M | $85.8M |
| Pre-Tax Income | $-372.8M | $297.9M | $470.4M | $-627.9M |
| Income Tax | $-158.6M | $-119.9M | $-91.4M | $-272.4M |
| Continuing Ops | $-214.1M | $417.8M | $561.8M | $-355.4M |
| Discontinued Ops | $-9.9M | $-3.0M | $-1.7M | $-732.0K |
| Net Income | $-224.1M | $414.8M | $560.1M | $-356.1M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-224.1M | $414.8M | $560.1M | $-356.1M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $2.61B | $3.44B | $4.63B | $4.17B |
| Cash & Equivalents | $881.5M | $1.51B | $2.41B | $1.39B |
| Accounts Receivable | $651.5M | $705.8M | $716.8M | $830.7M |
| Inventory | $714.1M | $597.0M | $480.4M | $417.0M |
| Other Current Assets | $359.1M | $626.3M | $1.02B | $1.53B |
| Long-Term Assets | $8.23B | $7.96B | $7.38B | $7.49B |
| Intangibles | $5.79B | $5.42B | $4.76B | $4.43B |
| Goodwill | $1.69B | $1.75B | $1.72B | $1.83B |
| Operating Leases | $73.3M | $65.3M | $53.6M | $58.9M |
| Other LT Assets | $668.7M | $721.4M | $857.6M | $1.18B |
| Total Assets | $10.84B | $11.39B | $12.01B | $11.66B |
| Current Liabilities | $933.2M | $1.54B | $1.04B | $2.24B |
| Accounts Payable | $90.8M | $102.8M | $77.9M | $122.1M |
| Current Debt | $31.0M | $605.0M | $31.0M | $1.03B |
| Current Leases | $15.6M | $19.0M | $14.3M | $14.3M |
| Deferred Revenue | $463.0K | $0 | — | — |
| Other Current Liab | $-7.8M | $16.1M | $4.4M | $42.1M |
| Long-Term Liabilities | $6.82B | $6.12B | $6.88B | $5.10B |
| Long-Term Debt | $5.69B | $5.11B | $6.08B | $4.33B |
| LT Operating Leases | $71.8M | $59.2M | $38.9M | $50.9M |
| Other LT Liab | $1.05B | $952.5M | $763.4M | $719.0M |
| Total Liabilities | $7.75B | $7.66B | $7.92B | $7.34B |
| Shareholders' Equity | $3.09B | $3.74B | $4.09B | $4.32B |
| Retained Earnings | $733.6M | $878.7M | $1.13B | $646.2M |
| AOCI | $-1.13B | $-842.1M | $-947.7M | $-568.6M |
| Total L&E | $10.84B | $11.39B | $12.01B | $11.66B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-224.1M | $414.8M | $560.1M | $-356.1M |
| Non-Cash Adjustments | $1.23B | $464.9M | $693.1M | $1.37B |
| Working Capital Changes | $267.6M | $212.3M | $142.7M | $345.5M |
| Cash from Operations | $1.27B | $1.09B | $1.40B | $1.36B |
| Capital Expenditures | $29.0M | $24.0M | $38.1M | $58.8M |
| Cash from Investing | $-446.2M | $-163.1M | $-508.2M | $-1.51B |
| Share Buybacks | $54.0K | $269.8M | $311.4M | $125.0M |
| Cash from Financing | $-529.5M | $-305.3M | $20.5M | $-873.4M |
| FX Effect | $-6.2M | $1.1M | $-1.7M | $6.6M |
| Net Change in Cash | $290.0M | $624.8M | $906.6M | $-1.02B |
| Beginning Cash | $591.4M | $881.5M | $1.51B | $2.41B |
| Ending Cash | $881.5M | $1.51B | $2.41B | $1.39B |
Frequently Asked Questions
How does Jazz Pharmaceuticals plc make money?
The company's revenue is driven by three primary pillars: Oncology, which includes proprietary cancer treatments; Orphan Drugs, focusing on rare diseases with significant unmet need; and Commercial Operations, encompassing manufacturing, sales, and marketing functions that support these therapeutic areas.
What are the main risks for JAZZ?
The stock faces significant risk from potential regulatory delays or rejections in developing new indications, which could impact pipeline valuation. Heavy reliance on a few blockbuster products exposes revenue to patent expirations or loss of exclusivity. The company operates with substantial debt levels and a negative net income trend in 2025, raising concerns about liquidity and cash burn sustainability.
What is JAZZ's competitive advantage?
Jazz possesses deep scientific expertise in complex disease mechanisms, particularly in oncology and orphan indications. The company benefits from a robust commercial infrastructure capable of navigating the specialized reimbursement landscapes required for high-cost biologics. Its portfolio consists of differentiated assets with strong intellectual property protection and established market footholds in key therapeutic niches.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.